A Fraser

A Hassan

A Pikul

A Shakeri

AL Schneider

AM Evans

Amin Salehi-Abargouei

AP Rolo

C Indiveri

Cain C. T. Clark

CJ Rebouche

CK Hyeon

CP Oliveira

CY Lim

D Rudman

DR Dufour

DS Pratt

E Kathirvel

E Ruttmann

EJ Sampson

ES Hong

F Galvano

F Hakeshzadeh

F Wroblewski

FAK Khazaal

Farzaneh Pirmadah

G Malaguarnera

G Musso

GV Purcell

H Jamilian

H Zhang

HA Mosah

HC Kim

I Delaš

İ Gülcin

J Mohtadinia

JB Whitfield

JC Bae

JC Santos

JG Rollason

JH An

JJ Zhang

JP Higgins

K Fukami

K Weibrecht

KE Lynch

L Kriston

L Schwingshackl

LA Videla

LE Arnold

M Karimi

M Malaguarnera

M Ohara

M Romano

M Tonelli

MH Somi

Mohammad Mohammadi

N Hongu

Nahid Ramezani-Jolfaie

Nasir Talenezhad

P Alavinejad

P Muriel

R DerSimonian

R Shang

RA Koeth

RB Singh

RJ Bloomer

RK Schindhelm

RR Mahale

S Alesci

S Benvenga

S Georgala

S Hatamkhani

S Li

S Neri

S Odo

S Shirali

SE Reuter

SG Wannamethee

SK Kunutsor

T Higuchi

Y Chen

Y Yonei

English

Background and aims: l-carnitine supplementation is proposed to reduce liver enzymes levels; however, previous findings were equivocal. The current systematic review and meta-analysis of randomized controlled clinical trials (RCTs) were performed to assess the effect of l-carnitine supplementation on serum levels of enzymes mainly produced by liver [alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGTP)]. Methods: Online databases as well as the reference lists of relevant studies were searched from inception up to June 2019. The risk of bias in individual studies was assessed using Cochrane Collaboration’s tool. Data were pooled using the random-effects model and expressed as mean differences (MDs) with 95% confidence intervals (CIs). Results: In total, 18 RCTs (1161 participants) met the eligibility criteria. l-carnitine supplementation dose ranged from 500 to 4000 mg/day. l-carnitine supplementation significantly reduced serum ALT (MD = − 8.65 IU/L, 95% CI − 13.40, − 3.90), AST (MD = − 8.52 IU/L, 95% CI − 12.16, − 4.89), and GGTP (MD = − 8.80 IU/L, 95% CI − 13.67, − 3.92) levels. The subgroup analysis showed that l-carnitine might be more effective in reducing the enzymes when supplemented in higher doses (≥ 2000 mg/day), for longer durations (&gt; 12 weeks), and among patients with liver diseases. The meta-evidence was graded as “moderate” for ALT and AST, and “low” for GGTP according to NutriGrade scoring system. Conclusion: l-carnitine supplementation significantly improves circulating ALT, AST and GGTP levels; therefore, it might positively affect liver function, especially among patients with liver diseases. Further high-quality RCTs are recommended to confirm our results.</p

Pirmadah, Farzaneh

Ramezani-Jolfaie, Nahid

Mohammadi, Mohammad

Talenezhad, Nasir

Clark, Cain

Salehi-Abargouei, Amin

Coventry University Pure Portal

Does L-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials

Crossref

Does l-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials

https://pure.coventry.ac.uk/ws/files/30676913/Post_Print.pdf

Does L-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials

Abstract

Similar works

Full text

Available Versions

Coventry University Pure Portal

Crossref